For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.
While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.
Different than value or growth investors, momentum-oriented investors live by the saying “the trend is your friend.” This investing style is all about taking advantage of upward or downward trends in a stock’s price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
San Diego, CA-based Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in CNS disorders and rare diseases.
ACAD boasts a Momentum Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Acadia Pharmaceuticals has seen some interesting price action recently; the stock is up 25% over the past one week and up 21.9% over the past four weeks. And in the last one-year period, ACAD has lost 18.5%. As for the stock’s trading volume, 1,386,877.63 shares on average were traded over the last 20 days.
Momentum investors also pay close attention to a company’s earnings. For ACAD, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.04 to $0.58 per share for 2024. ACAD boasts an average earnings surprise of 54.1%.
Investors should take the time to consider ACAD for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
This article was originally published here.
